Intervention Maps · Hyperlipidemia · Non-statin LDL medicines
Non-statin LDL medicines
This page is about medicines that lower LDL outside the statin class: ezetimibe, PCSK9 inhibitors, and bempedoic acid. They have event evidence in the pathways studied. That is a different decision from starting a statin, not a weaker grade of the same decision.
Bottom line
Non-statin LDL medicines stay on the map because ezetimibe and PCSK9 inhibitors reduce heart attack and stroke on statin backgrounds in the pooled package used here, without a clear all-cause or cardiovascular mortality benefit in that package, while intensive PCSK9 work preserves event benefit at very low LDL in ASCVD, and bempedoic acid reduces major cardiovascular events in statin-intolerant patients with gout and gallstone signals. Ezetimibe, PCSK9 inhibitors, and bempedoic acid remain distinct pathways. Statin intolerance is context, not a separate therapy and not a reason to skip the statin conversation.
What it is
Prescription options used when LDL needs further lowering on a statin background, or when a statin isn't tolerated. The main named options on this map are ezetimibe (usually a daily tablet), PCSK9 inhibitors (injectable pathways in the trials that matter here), and bempedoic acid (an oral option studied in statin-intolerant people).
What taking part usually involves
A clinician decides whether to add or switch based on your LDL response, prior events, side effects, and preferences about pills versus injections. Cost and access often shape what is realistic, especially for injectable pathways. Monitoring usually includes lipid checks. For bempedoic acid, gout and gallstone signals from the outcome package stay in view. This page is not a formulary or a “pick your shot” guide.
What it is commonly confused with
“If I can't take a statin, I just get a PCSK9 shot and the statin conversation is over.” “Event benefit means clear mortality proof for every drug in the class.” “These medicines replace lifestyle tools.” “All three options are interchangeable.”
What the evidence shows
In the pooled package used here, ezetimibe and PCSK9 inhibitors reduce heart attack and stroke when added to statin therapy, without a clear all-cause or cardiovascular mortality benefit in that pooled view. Absolute benefit concentrates at higher risk.
Landmark PCSK9 work in people with ASCVD on a statin background preserves event benefit even at very low LDL levels.
Bempedoic acid reduced a four-point major adverse cardiovascular event composite in statin-intolerant patients (hazard ratio about 0.87 in the CLEAR Outcomes package), with gout and gallstone signals to keep in view.
Statin intolerance is a real clinical context. It's not a separate therapy on this map, and it's not a license to skip the statin conversation when a statin might still be possible.
Who was studied, expectations, and limits
Population and context studied: adults on statin backgrounds in add-on trials, people with ASCVD in intensive PCSK9 pathways, and statin-intolerant adults in the bempedoic acid outcome trial.
That is the research setting, not a shopping recommendation.
Realistic expectation: these medicines can reduce heart attack and stroke in the pathways studied. Limits: clear mortality certainty is not the same claim; cost and injection burden can shape access, especially for PCSK9 pathways; they do not erase the statin page; class choice stays clinical.
Evidence consulted Open sources
Key sources used to prepare this answer. This is not a citation for every sentence.
← Back to Hyperlipidemia · find this again later from “What are you trying to figure out?”